Stockreport

AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration

AC Immune SA  (ACIU) 
Last ac immune sa earnings: 11/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
PDF First-in-class TDP-43 antibody developed using SurpraAntigen™ platform The only TDP-43 antibody with reported in vivo activity LAUSANNE, Switzerland, Aug. [Read more]